Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Sarclisa Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0161

    Sarclisa (isatuximab-irfc), Sarclisa Escena (isatuximab-irfc) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0161 alerts

    Get alerted when Policy CC-0161 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization for intravenous Sarclisa (isatuximab-irfc) and subcutaneous Sarclisa Escena in multiple myeloma. Coverage is based on age, diagnosis, prior therapy, transplant eligibility, disease status, and required combination regimens.

    Policy Summary
    PayerEmpire Bluecross
    PolicySarclisa (isatuximab-irfc), Sarclisa Escena (isatuximab-irfc) Coverage Criteria
    Policy CodePolicy CC-0161
    Change TypeModified
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable age, multiple-myeloma diagnosis, disease status, prior treatment history, transplant eligibility, and required combination regimen for medical-benefit review.
    SourceLink
    POLICY UPDATE CHANGES

    Sarclisa Escena (isatuximab-irfc) was added to the clinical criteria and coding.

    Coverage criteria were revised to permit Sarclisa IV after one prior line of therapy when used with pomalidomide and dexamethasone.

    The diagnosis coding range was expanded to C90.00-C90.32 for multiple myeloma and malignant plasma cell neoplasms.

    2 agentsDrugs covered by the policy
    4 pathwaysMultiple-myeloma clinical coverage pathways
    1-3 lines

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Permitted prior therapy range
    C90.00-C90.32Current ICD-10 diagnosis range
    3 codesTreatment and drug billing codes listed

    Coverage Criteria

    Initial therapy and relapsed/refractory multiple myeloma

    Coverage may be approved when the individual meets the age exception or any one of the multiple-myeloma treatment pathways below.

    Covered pathways

    • Age exception: Individual is under 19 years of ageAge <19 years
    • Relapsed or refractory disease with pomalidomide: Individual has multiple myeloma, has relapsed or refractory disease following at least one prior line of therapy including lenalidomide and a proteasome inhibitor, and uses Sarclisa or Sarclisa Escena in combination with pomalidomide and dexamethasone.At least 1 prior line including lenalidomide and a proteasome inhibitor

      Proteasome inhibitor examples include bortezomib, carfilzomib, or ixazomib.

    • Relapsed or refractory disease with carfilzomib: Individual has multiple myeloma, uses Sarclisa in combination with carfilzomib and dexamethasone, and has relapsed or refractory disease following one to three prior lines of therapy.1-3 prior lines of therapy
    • Primary therapy, transplant eligible

      • Permitted combinations

        • KRd: Carfilzomib, lenalidomide, and dexamethasone
        • VRd: Bortezomib, lenalidomide, and dexamethasone
    • Primary therapy, transplant ineligible or deferred

      • Permitted combinations

        • Rd: Lenalidomide and dexamethasone
        • VRd: Bortezomib, lenalidomide, and dexamethasone

    All other indications are excluded from approval. Coverage is limited to the approved or guideline-supported multiple-myeloma pathways, including specified relapsed or refractory disease and primary-therapy combination regimens.

    Use is not medically necessary when the request does not satisfy the applicable age, diagnosis, prior-treatment, disease-status, transplant-status, and combination-therapy requirements. Requests may also not be approved when the stated coverage criteria are not met.

    Sarclisa or Sarclisa Escena Initial Authorization

    Sarclisa or Sarclisa Escena initial authorization

    Approval may be granted when the individual is under 19 years of age or meets one of the covered multiple-myeloma treatment pathways.

    Initial authorization pathways

    • Age exception: Individual is under 19 years of ageAge <19 years
    • Covered multiple-myeloma treatment pathways

      • Relapsed or refractory disease with pomalidomide: Multiple myeloma with relapsed or refractory disease following at least one prior line of therapy including lenalidomide and a proteasome inhibitor; use with pomalidomide and dexamethasone.At least 1 prior line including lenalidomide and a proteasome inhibitor

    Billing and Diagnosis Codes

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Sarclisa Escena (isatuximab-irfc, subcutaneous)]
    J9227Injection, isatuximab-irfc, 10 mg (Effective 10/1/2020)
    J9999Not otherwise classified, antineoplastic drugs [when specified as Sarclisa Escena (isatuximab-irfc, subcutaneous)]
    ICD-10 DiagnosisICD-10
    C90.00-C90.32Multiple myeloma and malignant plasma cell neoplasms

    Provider Review and Authorization Actions

    Prior Authorization

    Submit clinical criteria for medical-benefit review

    Prior authorization or clinical review applies when Sarclisa or Sarclisa Escena is requested under the member’s medical benefit. Submit documentation of the applicable age, multiple-myeloma diagnosis, disease status, prior treatment history, transplant eligibility, and required combination regimen.

    • Age, when applicable
    • Multiple-myeloma diagnosis
    • Relapsed or refractory disease status and prior treatment history
    • Stem cell transplant eligibility or transplant deferral
    • Required combination regimen
    Denial Risk

    Criteria not met or unsupported indication

    Requests may not be approved when the applicable clinical criteria are not met or for all other indications. The request must satisfy the required age, diagnosis, prior-treatment, disease-status, transplant-status, and combination-therapy criteria.

    Therapy Background

    Sarclisa (isatuximab-irfc) is an anti-CD38 monoclonal antibody used in combination regimens for multiple myeloma. It is available as an intravenous product. Sarclisa Escena (isatuximab-irfc) is a subcutaneous formulation that may be administered by injection or an on-body injector and was found non-inferior to intravenous Sarclisa in efficacy, pharmacokinetics, and safety. The policy addresses use in relapsed or refractory disease and as primary therapy for individuals who are eligible or ineligible for autologous stem cell transplant.

    Definitions

    First-line therapy
    MeaningThe first or primary treatment for a diagnosis.
    When usedUsed as the initial treatment before subsequent lines of therapy.
    ExamplesMay include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
    Second-line therapy
    MeaningTreatment given after initial treatment is not effective.
    Alternative triggerMay be used when disease progression occurs after first-line therapy.
    Treatment sequence
    Policy Summary
    PayerEmpire Bluecross
    PolicySarclisa (isatuximab-irfc), Sarclisa Escena (isatuximab-irfc) Coverage Criteria
    Policy CodePolicy CC-0161
    Change TypeModified
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable age, multiple-myeloma diagnosis, disease status, prior treatment history, transplant eligibility, and required combination regimen for medical-benefit review.
    SourceLink
    On This Page
    Coverage CriteriaSarclisa or Sarclisa Escena Initial AuthorizationBilling and Diagnosis CodesProvider Review and Authorization ActionsTherapy BackgroundDefinitions
  1. Relapsed or refractory disease with carfilzomib: Multiple myeloma; use with carfilzomib and dexamethasone; relapsed or refractory disease following one to three prior lines of therapy.1-3 prior lines of therapy
  2. Primary therapy, transplant eligible: Multiple myeloma; primary therapy; eligible for stem cell transplant; and use with carfilzomib, lenalidomide, and dexamethasone or bortezomib, lenalidomide, and dexamethasone.Primary therapy; eligible for stem cell transplant
  3. Primary therapy, transplant ineligible or deferred: Multiple myeloma; primary therapy; not eligible for autologous stem cell transplant or transplant deferred; and use with lenalidomide and dexamethasone or bortezomib, lenalidomide, and dexamethasone.Primary therapy; ASCT ineligible or transplant deferred
    • Unapproved indications are excluded from approval.
    • Requests that do not meet the listed criteria may not be approved.
    Represents the line of therapy after first-line treatment.
    Third-line therapy
    MeaningTreatment given after both initial and second-line treatment are not effective.
    Alternative triggerMay be used when disease progression occurs after initial and second-line treatment.
    Treatment sequenceRepresents treatment after first-line and subsequent second-line therapy.
    Multiple myeloma
    Disease typeA type of cancer.
    Cell of originBegins in plasma cells.
    Plasma cellsPlasma cells are white blood cells that produce antibodies.
    Proteasome inhibitors
    Drug classA class of drugs used to treat multiple myeloma.
    MechanismWorks by blocking the action of proteasomes, which are cellular complexes that break down proteins.
    ExamplesExamples include bortezomib, carfilzomib, and ixazomib.
    Refractory disease
    MeaningIllness or disease that does not respond to treatment.
    Treatment responseThe disease remains unresponsive despite treatment.
    Clinical statusDescribes disease that is resistant to the treatment provided.
    Relapse or recurrence
    MeaningThe return of signs and symptoms of illness or disease.
    TimingOccurs after a period of improvement during which the disease could not be detected.
    Cancer recurrenceFor cancer, the disease may return at the original tumor site or in another place in the body.